Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.31 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.31 |
| ▸ | CYTH2 | Q99418 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18503846 | 0.84 | ENPP2 (0.56) | ENPP2PTGS2CYP4F2CYP4A11LMNA | |
| SCHEMBL17262659 | 0.80 | LMNA (0.44) | TTRLMNAAPLNRFYN | |
| SCHEMBL5897971 | 0.76 | ALDH1A1 (0.52) | ENPP2PTGS2LMNACYTH2 | |
| SCHEMBL16651363 | 0.75 | TTR (0.48) | ENPP2TTRLMNA | |
| SCHEMBL309415 | 0.74 | ENPP2 (0.46) | ENPP2PTGS2CYP4F2CYP4A11LMNA | |
| SCHEMBL13731463 | 0.74 | ENPP2 (0.46) | ENPP2PTGS2PTGS1CYP4F2CYP4A11 | |
| SCHEMBL13730896 | 0.74 | CA12 (0.50) | ENPP2PTGS2PTGS1 | |
| SCHEMBL30633579 | 0.74 | ENPP2 (0.46) | ENPP2PTGS2CYP4F2CYP4A11LMNA | |
| SCHEMBL13690334 | 0.74 | ACP1 (0.36) | ENPP2PTGS2LMNA | |
| SCHEMBL2550551 | 0.74 | PTGS2 (0.39) | ENPP2PTGS2FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093253-B2 | Leukotriene B4 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093253-B2 | Leukotriene B4 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093253-B2 | Leukotriene B4 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-01-10 | — | — | US | disclosed |
| CN-101970401-A | Leukotriene b4 inhibitors | HOFFMANN LA ROCHE | 2011-02-09 | — | — | CN | disclosed |
| EP-2250150-A1 | LEUKOTRIENE B4 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009109483-A1 | LEUKOTRIENE B4 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009109483-A1 | LEUKOTRIENE B4 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-11 | — | — | WO | disclosed |
| US-20090227603-A1 | LEUKOTRIENE B4 INHIBITORS | DOMINIQUE ROMYR | 2009-09-10 | — | — | US | disclosed |
| US-20090227603-A1 | LEUKOTRIENE B4 INHIBITORS | DOMINIQUE ROMYR | 2009-09-10 | — | — | US | disclosed |
| US-20090227603-A1 | LEUKOTRIENE B4 INHIBITORS | DOMINIQUE ROMYR | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227603-A1 | LEUKOTRIENE B4 INHIBITORS | LTB4R2, LTB4R, LTC4S | ENPP2 69/4885TTR 2572/4885PTGS2 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.